BTX - Brooklyn ImmunoTherapeutics completes $20 million financing

Brooklyn ImmunoTherapeutics ([[BTX]] +20.1%) has completed a $20M financing which it said would be used for the development of the mRNA gene editing and cell therapies technology licensed from Factor Biosciences and Novellus Therapeutics.The company expects to use the funds to begin translation of the gene-editing, cellular therapy, and nanolipid particle platforms towards clinical programs focused on orphan diseases such as sickle cell anemia, familial amyloidosis, and cell therapies for cancer, the company said.“Our exclusive license of Factor Biosciences and Novellus Therapeutics platform technology represents a key component in our overall corporate strategy,” noted Howard J. Federoff, CEO of Brooklyn ImmunoTherapeutics.In addition to a proprietary ToRNAdo lipid delivery system that is designed for efficient non-viral vector-based delivery of mRNA, the licensed platform includes an mRNA cell reprogramming method that can avoid off-target effects in combination with mRNA-based gene editing.In late April, Brooklyn ImmunoTherapeutics announced the acquisition of an exclusive license for

For further details see:

Brooklyn ImmunoTherapeutics completes $20 million financing